

I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on September 18, 2007

PATENT
Attorney Docket No.: 021819-000120US
Client Reference No.: JUV2879.54DIV

TOWNSEND and TOWNSEND and CREW LLP

By: Timothy S. Parker
Timothy S. Parker

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Steven W. Dow, et al.

Application No.: 10/772,913

Filed: February 5, 2004

For: SYSTEM IMMUNE ACTIVATION
METHOD USING NUCLEIC ACID-
LIPID COMPLEXES

Customer No. 20350

Confirmation No.: 5237

Examiner: WEHBE, Ann Marie Sabrina

Art Unit: 1633

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached forms PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of references BA-BE in compliance with the requirements of 37 CFR §1.98(a)(2) are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no


representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicants note that some or all of the references cited in this and in previous Information Disclosure Statements filed on November 10, 2006 and June 7, 2007 in the instant application were also made of record via Information Disclosure Statements filed, or in Office Actions issued, in U.S. Patent Application Nos. 09/104,759, filed June 25, 1998, now issued U.S. Patent No. 6,693,086 (Attorney Docket No. 021819-000100US), further 10/012,597, filed November 30, 2001 (Attorney Docket No. 021819-000110US) (now abandoned), 11/320,019, filed December 27, 2005 (Attorney Docket No. 021819-000111US), 10/780,114, filed February 17, 2004 (Attorney Docket No. 021819-000130US) and 10/780,294, filed February 17, 2004 (Attorney Docket No. 021819-000200US). Copies of the Information Disclosure Statements and/or Office Actions in these related cases are available on Public PAIR and are believed to be readily accessible to the Examiner.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Karen B. Dow
Reg. No. 29,684

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 858-350-6100
Fax: 858-350-6111
KBD:tsp

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/772,913		
		Filing Date	February 5, 2004		
		First Named Inventor	Dow, Steven W.		
		Art Unit	1633		
		Examiner Name	WEHBE, Ann Marie Sabrina		
Sheet	1	of	2	Attorney Docket Number	021819-000120US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	AA	US-5,935,568	08/10/1999	Dow, et al.	
	AB	US-6,316,024	11/13/2001	Allen, et al.	
	AC	US-			
	AD	US-			
	AE	US-			
	AF	US-			
	AG	US-			
	AH	US-			
	AI	US-			
	AJ	US-			
	AK	US-			
	AL	US-			
	AM	US-			
	AN	US-			
	AO	US-			
	AP	US-			
	AQ	US-			
	AR	US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AS							<input type="checkbox"/>
	AT							<input type="checkbox"/>
	AU							<input type="checkbox"/>
	AV							<input type="checkbox"/>
	AW							<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/772,913
				Filing Date	February 5, 2004
				First Named Inventor	Dow, Steven W.
				Art Unit	1633
				Examiner Name	WEHBE, Ann Marie Sabrina
Sheet	2	of	2	Attorney Docket Number	021819-000120US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BA	KRIEG, Arthur M., et al. "Oligodeoxynucleotide Modifications Determine the Magnitude of B Cell Stimuation by CpG Motifs", <i>Antisense & Nucl. Acid Drug Dev</i> (1996) 6:133-139	<input type="checkbox"/>
	BB	KRIEG, Arthur M., et al. "CpG motifs in bacterial DNA trigger direct B-cell activation", <i>Nature (Lond.)</i> (1995) 374:546-549	<input type="checkbox"/>
	BC	SPARWASSER, Tim, et al. "Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells", <i>Eur J. Immunol</i> (1998) 28:2045-2054	<input type="checkbox"/>
	BD	WEINER, George J., et al. "Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization", <i>PNAS (USA)</i> (1997) 94:10833-10837	<input type="checkbox"/>
	BE	ZHAO, Qiuyan, et al. "Comparison of Cellular Binding and Uptake of Antisense Phosphodiester, Phosphorothioate, and Mixed Phosphorothioate and Methylphosphonate Oligonucleotides", <i>Antisense Res and Dev</i> (1993) 3:53-66	<input type="checkbox"/>
	BF		<input type="checkbox"/>
	BG		<input type="checkbox"/>
	BH		<input type="checkbox"/>
	BI		<input type="checkbox"/>
	BJ		<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.